Issue of Convertible Loan Notes and Warrants
Released : Jun 17, 2014
17 June 2014
TIZIANA LIFE SCIENCES PLC
ISSUE OF CONVERTIBLE LOAN NOTES AND WARRANTS
CHANGE OF REGISTERED OFFICE
London, 17 June 2014 - Tiziana Life Sciences plc (AIM: TILS) (the "Company"), a UK biotechnology company with a focus on therapeutic and diagnostic applications for cancer, is pleased to announce that the Company has issued £1,451,472 convertible loan notes ("Convertible Loan Notes"), which also carry warrants ("Warrants") to subscribe for an additional 1,995,774 ordinary shares of £0.03 each in the capital of the Company ("Ordinary Shares").
The Convertible Loan Notes carry interest at 6 per cent per annum payable in Ordinary Shares at the date of conversion. The Convertible Loan Notes and interest accrued thereon convert into Ordinary Shares at a conversion price of 24 pence per share and are restricted from conversion at any time before 28 March 2015.
The Warrants, which have been issued on the basis of 11 Warrants for each £8 of Convertible Loan Notes, contain a right to subscribe for Ordinary Shares at a price of 32 pence each and are restricted from exercise prior to 29 March 2015 and subsequent to 28 March 2017.
The proceeds from the issue of the Convertible Loan Notes will further strengthen the Company's balance sheet and be used for the development of the Company's intellectual property and for general working capital purposes.
The Company also confirms that it has changed its registered office address to 18 South Street, Mayfair, London W1K 1DG.
Contacts:
| Tiziana Life Sciences PLC Philip Boyd |
+44 (0)20 7493 2853 |
| Cairn Financial Advisers LLP Nominated Adviser Liam Murray / Avi Robinson |
+44 (0)20 7148 7900 |
| Beaufort Securities Limited Broker Saif Janjua |
+44 (0)20 7382 8300 |
| FTI Consulting Limited John Dineen |
+44 (0)20 3727 1136 |
About Tiziana Life Sciences
Tiziana Life Sciences is a UK biotechnology company whose mission is to discover and develop novel molecules that impact human disease in the area of oncology, with a particular focus on metastatic cancers.
For more information go to http://www.tizianalifesciences.com
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Tiziana Life Sciences PLC via Globenewswire
HUG#1793639